Exicure Submits Q1 Quarterly Report to SEC

by Jang Hyowon

Published 05 Aug.2025 09:58(KST)

Exicurehighton, a KOSPI-listed company, announced on August 5 that its U.S. subsidiary, Exicure, Inc., has submitted its quarterly report (Form 10-Q) for the first quarter of this year to the U.S. financial authorities.

According to Exicurehighton, Exicure, its subsidiary developing treatments for blood disorders, submitted its regular Form 10-Q quarterly report to the Nasdaq Securities and Exchange Commission (SEC) as of July 1. Previously, Exicure failed to submit its first quarter 2025 quarterly report on time and reportedly received a deficiency notice from Nasdaq in May.

Exicure stated that it submitted the quarterly report within the required period in accordance with Nasdaq listing rules and received a notice from the Nasdaq listing qualifications department confirming compliance and resolving the issue.

Exicure is a biotechnology company focused on developing nucleic acid therapeutics targeting ribonucleic acid. Its parent company, Exicurehighton, participated in Exicure's paid-in capital increase last year, investing $10 million (approximately KRW 13.8 billion), and incorporated Exicure as a subsidiary. As of the end of the first quarter, Exicurehighton holds a 52.76% stake. Exicurehighton is a KOSPI-listed company that provides security video solutions, including AI CCTV.